Mutations of the BRAF gene in benign and malignant melanocytic lesions

被引:174
作者
Yazdi, AS
Palmedo, G
Flaig, MJ
Puchta, U
Reckwerth, A
Rütten, A
Mentzel, T
Hügel, H
Hantschke, M
Schmid-Wendtner, MH
Kutzner, H
Sander, CA
机构
[1] Univ Munich, Dept Dermatol, D-8000 Munich, Germany
[2] Dermatohistopathol Gemeinschaftspraxis, Friedrichshafen, Germany
关键词
b-raf; nevus; point mutation;
D O I
10.1046/j.1523-1747.2003.12559.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
A single-point mutation in exon 15 of the BRAF gene has recently been reported in a high percentage in cultured melanoma cells and in 6 of 9 primary melanomas examined. To evaluate the impact of the T1796A BRAF mutation, we screened primary melanomas, various types of nevi and lesions where a melanoma developed in an underlying nevus. We could detect the mutation in 28 of 97 (29%) melanomas and in 39 of 187 (21%) nevi, including blue nevi (0/20) and Spitz nevi (0/69), which did not carry the mutation. In melanomas with an underlying nevus, either the mutation was present in both the laser-microdissected nevus cells and the laser-microdissected melanoma cells (3/14) or both lesions were negative for the BRAF mutation except one case. In conclusion, mutations in exon 15 of the BRAF gene are nonspecific for progression of a nevus to a melanoma. Other so far unknown cofactors seem to be of importance.
引用
收藏
页码:1160 / 1162
页数:3
相关论文
共 16 条
[1]   Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features [J].
Bastian, BC ;
LeBoit, PE ;
Pinkel, D .
AMERICAN JOURNAL OF PATHOLOGY, 2000, 157 (03) :967-972
[2]  
Campisi J, 2000, IN VIVO, V14, P183
[3]  
Cohen C, 2002, CLIN CANCER RES, V8, P3728
[4]   Mutations of the BRAF gene in human cancer [J].
Davies, H ;
Bignell, GR ;
Cox, C ;
Stephens, P ;
Edkins, S ;
Clegg, S ;
Teague, J ;
Woffendin, H ;
Garnett, MJ ;
Bottomley, W ;
Davis, N ;
Dicks, N ;
Ewing, R ;
Floyd, Y ;
Gray, K ;
Hall, S ;
Hawes, R ;
Hughes, J ;
Kosmidou, V ;
Menzies, A ;
Mould, C ;
Parker, A ;
Stevens, C ;
Watt, S ;
Hooper, S ;
Wilson, R ;
Jayatilake, H ;
Gusterson, BA ;
Cooper, C ;
Shipley, J ;
Hargrave, D ;
Pritchard-Jones, K ;
Maitland, N ;
Chenevix-Trench, G ;
Riggins, GJ ;
Bigner, DD ;
Palmieri, G ;
Cossu, A ;
Flanagan, A ;
Nicholson, A ;
Ho, JWC ;
Leung, SY ;
Yuen, ST ;
Weber, BL ;
Siegler, HF ;
Darrow, TL ;
Paterson, H ;
Marais, R ;
Marshall, CJ ;
Wooster, R .
NATURE, 2002, 417 (6892) :949-954
[5]   Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [J].
Druker, BJ ;
Talpaz, M ;
Resta, DJ ;
Peng, B ;
Buchdunger, E ;
Ford, JM ;
Lydon, NB ;
Kantarjian, H ;
Capdeville, R ;
Ohno-Jones, S ;
Sawyers, CL .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1031-1037
[6]   Identification of a novel inhibitor of mitogen-activated protein kinase kinase [J].
Favata, MF ;
Horiuchi, KY ;
Manos, EJ ;
Daulerio, AJ ;
Stradley, DA ;
Feeser, WS ;
Van Dyk, DE ;
Pitts, WJ ;
Earl, RA ;
Hobbs, F ;
Copeland, RA ;
Magolda, RL ;
Scherle, PA ;
Trzaskos, JM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (29) :18623-18632
[7]   Malignant transformation of melanocytes to melanoma by constitutive activation of mitogen-activated protein kinase kinase (MAPKK) signaling [J].
Govindarajan, B ;
Bai, XH ;
Cohen, C ;
Zhong, H ;
Kilroy, S ;
Louis, G ;
Moses, M ;
Arbiser, JL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (11) :9790-9795
[8]   The hallmarks of cancer [J].
Hanahan, D ;
Weinberg, RA .
CELL, 2000, 100 (01) :57-70
[9]   A melanoma-predisposing germline CDKN2A mutation with functional significance for both p16 and p14ARF [J].
Hashemi, J ;
Lindström, MS ;
Asker, C ;
Platz, A ;
Hansson, J ;
Wiman, KG .
CANCER LETTERS, 2002, 180 (02) :211-221
[10]   Absence of exon 15 BRAF germline mutations in familial melanoma [J].
Lang, J ;
Boxer, M ;
MacKie, R .
HUMAN MUTATION, 2003, 21 (03) :327-330